Icahn, Byetta Sales Boost Amylin (Update)
- Loading Comments...
Updated from 3:19 p.m. EST
Amylin Pharmaceuticals' (AMLN Quote) got a strong boost Monday from an uptick in prescription numbers for diabetes drug Byetta and news that Carl Icahn has been increasing his stake in the biotech stock.
Overall prescriptions of Byetta -- although still down 9% year over year -- increased 3.9% during the first week of November, according to new IMS data. Also on Monday, CNBC's Mike Huckman reported that Icahn recently increased his stake in the company.
The billionaire, activist investor disclosed holding about 10.7 million shares of Amylin at the end of the most recent quarter, up from roughly 6.8 million shares at the close of the second quarter, according to a Friday filing with the Securities and Exchange Commission. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,358.52 | 1,097.39 | 2,151.60 | 32.20 |
Oil *
77.25
|
|
DOWN
105.88
|
DOWN
13.24
|
DOWN
24.45
|
DOWN
0.59
|
10 Yr
3.22%
SPDR Gold
115.31
|
|
-1.01%
|
-1.19%
|
-1.12%
|
-1.80%
|
Data delayed 20 minutes |
Connect with TheStreet